SYKStryker Corporation

$329.65

The financials

Stryker Corporation by the numbers

Stryker Corporation (SYK) reported revenue of $6.59B in Q2 2026 (quarter ended June 30, 2026), up 9.4% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $1.28B (19% of revenue). For the full year FY2025, revenue was $25.1B (+11% year on year) and net income $3.25B. Its largest product in 2026-Q1 was Instruments at $920M, 15% of the disclosed total, just ahead of Medical at 14%.

Stryker Corporation income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$6.59B$6.02B+9.4%
Gross profit$4.50B$3.84B+17%
Operating income$1.66B$1.11B+49%
Net income$1.28B$884M+44%
Diluted EPS$3.30$2.29+44%
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Instruments$920M15%
Medical$902M14%
Endoscopy$868M14%
Knees$670M11%
Ortho Tech$646M10%
Neuro Cranial Instruments$606M9.7%
Neurovascular$517M8.3%
Orthopaedic Instruments$489M7.8%
Hips$460M7.3%
Other Orthopedics$157M2.5%
Enabling Technologies$26M0.4%
Spinal Implants$2.0M0.0%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $6.26B (+23%)
Neurovascular grew +27% year on yearSpinal Implants -99% year on year
  • Instruments$920.0MQoQ +21%year on year +9.8%
  • Medical$902.0MQoQ -8.4%year on year -4.6%
  • Endoscopy$868.0MQoQ -3.1%year on year +0.12%
  • Knees$670.0MQoQ +6.7%year on year +4.9%
  • Ortho Tech$646.0MQoQ -year on year +4.7%
  • Neuro Cranial Instruments$606.0MQoQ -year on year +7.6%
  • Neurovascular$517.0MQoQ -1.5%year on year +27%
  • Orthopaedic Instruments$489.0MQoQ -year on year +1.0%
  • Hips$460.0MQoQ +0.66%year on year +3.8%
  • Other Orthopedics$157.0MQoQ -year on year +18%
  • Enabling Technologies$26.0MQoQ -year on year -10%
  • Spinal Implants$2.0MQoQ -year on year -99%
  • Neuro Cranial Interventional Spine-QoQ -year on year -
  • Neuro Cranial-QoQ -year on year -
  • Other Orthopaedics-QoQ -year on year -
  • Other Orthopedics Enabling Technologies-QoQ -year on year -
  • Spine-QoQ -year on year -
Segment sum = 104% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-11, SEC EDGAR